Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
March 2005   
April 2005   
June 2005   
July 2005   
August 2005   
September 2005   
October 2005   
November 2005   
May 2006   
June 2006   
July 2006   
October 2006   
April 2010   
May 2013   
June 2013   
July 2013   
August 2013   
July 2014   
November 2014   
January 2015   
February 2015   
April 2015   
July 2015   
January 2016   
March 2016   

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
Medical Director-Rocky Mountain MS Center

Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore

This page is powered by Blogger. Isn't yours?



Gilyena gets a thumbs-up in Europe to go along with U.S. approval

BASEL, Switzerland—Novartis AG won approval from the European Commission for Gilenya (fingolimod) 0.5 mg daily as a disease-modifying therapy in patients with highly active relapsing-remitting multiple sclerosis (RRMS) despite treatment with beta interferon, or in patients with rapidly evolving severe RRMS—making it the first approved oral MS treatment in the European Union (EU). The approval was based on the largest clinical trial program submitted to date for a new multiple sclerosis drug, and included data from clinical studies showing significant efficacy in reducing relapses, the risk of disability progression and the number of brain lesions detected by magnetic resonance imaging.

David Epstein, division head of Novartis Pharmaceuticals, says that the announcement marks another "major regulatory approval and we are pleased that Gilenya will become available to more eligible MS patients. Novartis is dedicated to bringing innovative new treatments to patients where there is significant unmet need. Gilenya has been in clinical development for MS since 2003 and we are grateful for the commitment of those involved, especially the trial participants, who have contributed significantly to the development of this novel medicine."

This approval follows the news in September 2010 that the U.S. Food and Drug Administration (FDA) had approved the drug for relapsing forms of MS—the most common forms of the disease.

Gilenya, the first in a new class of drugs called sphingosine 1-phosphate receptor (S1PR) modulators, was licensed from Mitsubishi Tanabe Pharma Corp. The novel mechanism of Gilenya is thought to work by reducing the immune system's attack on the central nervous system in MS patients by retaining certain white blood cells (lymphocytes) in the lymph nodes. This prevents the white blood cells from reaching the central nervous system, where they could potentially attack the protective covering around the nerve fibers, resulting in less inflammatory damage to the nerve cells. The white blood cell retention is reversible if Gilenya treatment is stopped.

The EU application included data showing that this approved dosage of Gilenya reduced relapses by 52 percent at one year compared with interferon beta-1a IM (Avonex), one of the most commonly prescribed treatments for MS. Data from a two-year placebo-controlled study showed a 30 percent reduction in the risk of disability progression among Gilenya patients compared with placebo), and clinical studies also indicated that treatment with Gilenya resulted in "statistically significant" reductions in brain lesion activity as measured by MRI.

Also statistically significant could be the payoff from prescriptions of the drug, with healthcare analyst Trung Huynh at Datamonitor noting: "European approval is set to boost sales another $900 million as Novartis become the leading player in this lucrative multibillion dollar market."

Some estimates by analysts point to the MS market growing to $15 billion by 2015, and many expect that Novartis will be one of the major beneficiaries of this growth because, as some have noted, many newly diagnosed MS patients will likely begin therapy with Gilenya rather than with older treatments.

Story Source: The above story is based on materials provided by DDNEWS
Note: Materials may be edited for content and length